Effects Of Statin Treatment And Supplemental Co Q10 On C2C12 Myotubes

Hill, Cynthia F. C.; Schwartz, Lawrence M.; Thompson, Paul D.; Clarkson, Priscilla M.

doi:10.1249/00005768-200505001-02436

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significantly shorter latency with rechallenge is compatible with postulated mechanisms of the adverse effects of statins, including reduced levels of coenzyme Q 10 , 48 partially reversible mitochondrial injury, 7 and injury to muscle satellite cells. 49,50 The study findings suggest that although new development of MAEs taper with duration of time receiving statin therapy, there may be no time period of successful, symptom-free statin use that guarantees future freedom from statinassociated MAEs.…”

Section: Discussionmentioning

confidence: 93%

“…In addition, evidence suggests that statins may be toxic to muscle satellite cells (i.e., the muscle stem cells that enable regeneration and repair after injury). 49 Thus, symptoms may arise in some patients only after accrued muscle wear and tear without repair that surpasses a clinical threshold. 50 (Mitochondrial effects are also well recognized to progress subclinically until clinical thresholds are achieved.)…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients

et al. 2010

View full text Add to dashboard Cite

Study Objective To characterize the properties and natural history of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)-associated muscle-related adverse effects (MAEs). Design Patient-targeted postmarketing adverse-effect surveillance approach coupling survey design with an open-ended narrative. Setting University-affiliated health care system. Subjects Three hundred fifty-four patients (age range 34–86 yrs) who self-reported muscle-related problems associated with statin therapy. Measurements and Main Results Patients with perceived statin-associated MAEs completed a survey assessing statin drugs and dosages; characteristics of the MAEs; time course of onset, resolution, or recurrence; and impact on quality of life (QOL). Cases were assessed for putative drug adverse-effect causality by using the Naranjo adverse drug reaction probability scale criteria and were evaluated for inclusion in groups for which mortality benefit with statins has been shown. Patients reported muscle pain (93%), fatigue (88%), and weakness (85%). Three hundred patients (85%) met literature criteria for probable or definite drug adverse-effect causality. Ninety-four percent of atorvastatin usages (240/255) generated MAEs versus 61% of lovastatin usages (38/62, p<0.0001). Higher potency statins reproduced MAEs in 100% of 39 rechallenges versus 73% (29/40) with lower potency rechallenges (p<0.01). Time course of onset after statin initiation varied (median 14 wks); some MAEs occurred after long-term symptom-free use. Recurrence with rechallenge had a significantly shorter latency to onset (median 2 wks). The MAEs adversely affected all assessed functional and QOL domains. Most patients with probable or definite MAEs were in categories for which available randomized controlled trial evidence shows no trend to all-cause mortality benefit with statin therapy. Conclusion This study complements available information on the properties and natural history of statin-associated MAEs, affirming dose dependence and strong QOL impact. The data indicating a dose-dependent relationship between MAE risk and recurrence suggest lower potency statins or discontinuation may bear consideration for ameliorating symptoms.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[19] In addition to its lipidlowering effects, statins also have positive effects on endothelial function, nitric oxide bioavailability, antioxidant properties, stabilization of atherosclerotic plaques, and vascular inflammation. [20] In our study, statin was given in rats with normal lipid profiles. However our results revealed significant decrease in LDL cholesterol and triglyceride levels in the statin group.…”

Section: Discussionmentioning

confidence: 93%

The effect of atorvastatin on penile intracavernosal pressure and cavernosal morphology in normocholesterolemic rats

Bolat¹,

Bakırtaş²,

Fırat³

et al. 2019

Turkish Journal of Urology

View full text Add to dashboard Cite

The present study showed that the use of atorvastatin reduced the intracavernosal pressure in 10 V stimulation, and minimally decreased testosterone levels in rats, within a short period of time. When statin treatment is considered for its protective properties on cardiovascular system or for its lipid-lowering effect. It should be kept in mind that atorvastatin may also adversely contribute to erectile dysfunction.

show abstract

Effects Of Statin Treatment And Supplemental Co Q10 On C2C12 Myotubes

Cited by 2 publications

References 0 publications

Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients

Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients

The effect of atorvastatin on penile intracavernosal pressure and cavernosal morphology in normocholesterolemic rats

Contact Info

Product

Resources

About